



Federal Employee Program.

OREXIN ANTAGONISTS

BELSOMRA (suvorexant), DAYVIGO (lemborexant), QUVIVIQ* (daridorexant)

*Prior authorization for the brand formulation applies only to formulary exceptions due to being a non-covered medication

Pre - PA Allowance

Age 18 years of age and older

Quantity One 30 day supply per 365 days

| Medication/Strength | Quantity Limit per 30 days |
|---------------------|----------------------------|
| Belsomra 5mg | 30 |
| Belsomra 10mg | 30 |
| Belsomra 15mg | 30 |
| Belsomra 20mg | 30 |
| Dayvigo 5mg | 30 |
| Dayvigo 10mg | 30 |

Prior-Approval Requirements

Age 18 years of age and older

Diagnosis

Patient must have the following:

1. Insomnia - a persistent disorder of initiating or maintaining sleep

AND ALL of the following:

- a. Prescriber agrees to discontinue medication if patient experiences a complex sleep behavior (e.g., sleepwalking, sleep-driving, etc.)
- b. **NO** narcolepsy
- c. **NO** concurrent therapy with another Prior Authorization (PA) sleep aid (see Appendix 1) or with an oxybate product (see Appendix 2)

Prior - Approval Limits

Quantity

| Medication/Strength | Quantity Limit |
|---------------------|----------------|
| Belsomra 5mg | |
| Belsomra 10mg | |
| Belsomra 15mg | |
| Belsomra 20mg | |

90 tablets per 90 days **OR**



Federal Employee Program.

OREXIN ANTAGONISTS

BELSOMRA (suvorexant), DAYVIGO (lemborexant), QUVIVIQ* (daridorexant)

*Prior authorization for the brand formulation applies only to formulary exceptions due to being a non-covered medication

| | |
|--------------|----------------------------------|
| Dayvigo 5mg | 90 tablets per 90 days OR |
| Dayvigo 10mg | |

| <u>Medication/Strength with Approved Formulary Exception Only</u> | <u>Quantity Limit</u> |
|---|------------------------|
| Quviviq 25mg | 90 tablets per 90 days |
| Quviviq 50mg | |

Duration 12 months

Prior – Approval Renewal Requirements

Same as above

Prior - Approval Renewal Limits

Same as above

Appendix 1 - List of Prior Authorization (PA) Sleep Aids

| Generic Name | Brand Name |
|---------------------------|------------|
| daridorexant | Quviviq |
| estazolam | Prosom |
| eszopiclone | Lunesta |
| flurazepam | Dalmane |
| lemborexant | Dayvigo |
| quazepam | Doral |
| ramelteon | Rozerem |
| tasimelteon | Hetlioz |
| suvorexant | Belsomra |
| temazepam | Restoril |
| triazolam | Halcion |
| zaleplon | Sonata |
| zolpidem | Ambien |
| zolpidem extended-release | Ambien CR |
| zolpidem oral spray | Zolpimist |
| zolpidem sublingual | Edluar |



Federal Employee Program.

OREXIN ANTAGONISTS

BELSOMRA (suvorexant), DAYVIGO (lemborexant), QUVIVIQ* (daridorexant)

*Prior authorization for the brand formulation applies only to formulary exceptions due to being a non-covered medication

| | |
|---------------------|------------|
| zolpidem sublingual | Intermezzo |
|---------------------|------------|

Appendix 2 - List of Oxybate Products

| Generic Name | Brand Name |
|--|------------|
| sodium oxybate | Lumryz |
| sodium oxybate | Xyrem |
| calcium, magnesium, potassium, sodium oxybates | Xywav |